Business
Voro Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance PrimeBody™ Technology for Next-Generation Tumor-Activated ADCs
SAN DIEGO, March 17, 2026--Voro Therapeutics, a biotechnology company pioneering tumor-activated biologics using its proprietary PrimeBody platform, today announced a research collaboration with Daiichi Sankyo (TSE: 4568) through its Daiichi Sankyo Research Institute San Diego.
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":256,"url":"https://media.zenfs.com/en/business-wire.com/d7ae3faf5f13b65629b5686fff01fa32"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aJ7ZMqOz60U25rzhai204w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUxMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d7ae3faf5f13b65629b5686fff01fa32","width":480,"height":256}},"lazy":false},{"type":"text","content":"Collaboration will leverage Voro's PrimeBody platform to advance tumor-activated antibody drug conjugates designed to expand therapeutic index and enhance precision targeting","length":178,"tagName":"p"},{"type":"text","content":"SAN DIEGO, March 17, 2026--(BUSINESS WIRE)--Voro Therapeutics, a biotechnology company pioneering tumor-activated biologics using its proprietary PrimeBody platform, today announced a research collaboration with Daiichi Sankyo (TSE: 4568) through its Daiichi Sankyo Research Institute San Diego.","length":295,"tagName":"p"},{"type":"text","content":"The collaboration will evaluate Voro’s PrimeBody platform to generate masked antibody drug conjugate (ADC) candidates designed to improve therapeutic index through tumor-selective activation by incorporating proprietary masking domains and protease-cleavable linkers to keep biologics inactive in circulation and healthy tissues, with activation occurring selectively within the tumor microenvironment.","length":402,"tagName":"p"},{"type":"text","content":""Unlocking the full potential of highly potent payloads requires a new level of control over where and when activation occurs," said Ugur Eskiocak, Ph.D., Co-Founder and CEO of Voro Therapeutics. "PrimeBody is designed to potentially provide that level of control through tumor-selective activation and expand the target universe to include antigens historically considered too broadly expressed. We believe this approach has the potential to fundamentally expand the therapeutic index of ADCs. We are excited to collaborate with Daiichi Sankyo, a global leader in ADC innovation with a proven track record of developing transformative medicines for patients."","length":680,"tagName":"p"},{"type":"text","content":"Under the agreement, Voro Therapeutics will apply its PrimeBody masking and linker te...